When is PCSK9 (proprotein convertase subtilisin/kexin type‑9) genetic testing indicated and what PCSK9‑inhibitor (alirocumab, evolocumab) therapy is recommended for patients with severe or refractory hypercholesterolemia who do not achieve low‑density lipoprotein cholesterol (LDL‑C) targets on maximally tolerated statin therapy ± ezetimibe?

PCSK9 Genetic Testing and PCSK9-Inhibitor Therapy for Refractory Hypercholesterolemia

PCSK9 Genetic Testing Indications

PCSK9 genetic testing is not routinely indicated for clinical decision-making regarding PCSK9-inhibitor therapy. Treatment decisions are based on clinical phenotype (LDL-C levels, cardiovascular risk, and response to statins) rather than genetic testing. 1

When Genetic Testing May Be Considered

• Homozygous familial hypercholesterolemia (HoFH): LDLR mutation testing (not PCSK9 testing) is critical because patients with negative/negative LDLR mutations (LDL receptor activity <2%) show minimal or no response to PCSK9 inhibitors. 1
• Research or cascade screening contexts: PCSK9 gain-of-function mutations cause a rare form of familial hypercholesterolemia, but identifying these mutations does not change the treatment algorithm—these patients still receive PCSK9 inhibitors based on clinical criteria. 1

Key caveat: The presence or absence of PCSK9 mutations does not determine eligibility for PCSK9-inhibitor therapy in clinical practice. 1

---

PCSK9-Inhibitor Therapy Recommendations

Step 1: Confirm Maximally Tolerated Background Therapy

Before considering PCSK9 inhibitors, ensure the patient is on maximally tolerated statin ± ezetimibe and verify medication adherence. 1

• Check adherence first and reinforce the importance of treatment compliance. 1
• If adherence is satisfactory, add ezetimibe 10 mg daily (provides 15–20% additional LDL-C reduction). 1
• Reassess LDL-C after 4 weeks of ezetimibe therapy. 1

---

Step 2: Identify Patients Who Qualify for PCSK9 Inhibitors

PCSK9 inhibitors (alirocumab or evolocumab) should be considered in three specific patient groups: 1

Group 1: Patients with Established ASCVD

• LDL-C threshold >4.5 mmol/L (>180 mg/dL) despite maximally tolerated statin ± ezetimibe. 1
• Lower threshold >3.6 mmol/L (>140 mg/dL) if additional high-risk features are present: 1
  • Concomitant familial hypercholesterolemia
  • Diabetes mellitus with target organ damage (e.g., proteinuria) or marked hypertension (≥160/100 mmHg)
  • Severe/extensive ASCVD (e.g., polyvascular disease, extensive coronary disease)
  • Rapid progression of ASCVD (repeated ACS, unplanned revascularizations, or ischemic strokes within 5 years)

Group 2: Statin-Intolerant Patients with ASCVD

• Patients who do not tolerate appropriate doses of at least three different statins and have elevated LDL-C levels. 1
• These patients should still be on ezetimibe before adding a PCSK9 inhibitor. 2

Group 3: Familial Hypercholesterolemia Without Clinical ASCVD

• LDL-C >4.5 mmol/L (>180 mg/dL) despite maximally tolerated statin plus ezetimibe. 1
• Lower threshold >3.6 mmol/L (>140 mg/dL) if additional risk factors are present: 1
  • Diabetes with target organ damage or marked hypertension
  • Lipoprotein(a) >50 mg/dL
  • Major risk factors (smoking, marked hypertension)
  • Age >40 years without treatment
  • Premature ASCVD in first-degree relatives (<55 years in males, <60 years in females)
  • Imaging evidence of increased atherosclerotic burden (e.g., coronary CTA showing >50% stenosis or mixed/non-calcified plaques)

---

Step 3: Choose Between Alirocumab and Evolocumab

Both alirocumab and evolocumab are equally effective, reducing LDL-C by approximately 50–60%. 1, 3, 4, 5

• Dosing options: 3
  • Evolocumab: 140 mg subcutaneously every 2 weeks OR 420 mg monthly
  • Alirocumab: 75–150 mg subcutaneously every 2 weeks
• Choice is based on patient preference, insurance coverage, and cost. 2, 3

---

Step 4: Monitor Response and Adjust Therapy

• Reassess LDL-C 4–12 weeks after initiating PCSK9-inhibitor therapy. 1, 3
• Target LDL-C goals: 1
  • Very high-risk patients (established ASCVD): <1.4 mmol/L (<55 mg/dL) with ≥50% reduction from baseline
  • High-risk patients (FH without ASCVD): <1.8 mmol/L (<70 mg/dL)
• If no clinically meaningful response in HoFH patients after 12 weeks, consider increasing evolocumab to 420 mg every 2 weeks (though response depends on residual LDL receptor activity). 1, 5

---

Mechanism of Action and Safety

PCSK9 inhibitors work by binding circulating PCSK9, preventing it from degrading LDL receptors on hepatocytes. This increases LDL receptor availability, enhancing LDL-C clearance from the bloodstream. 1, 4, 6

• Complementary to statins and ezetimibe: Statins upregulate both LDLR and PCSK9 expression; PCSK9 inhibitors block the PCSK9-mediated degradation of LDLR, resulting in synergistic LDL-C lowering. 1, 4
• Safety profile: Well-tolerated with minimal muscle-related adverse effects. 3, 5, 7 Injection-site reactions occur in <5% of patients. 3 No increase in neurocognitive events, new-onset diabetes, or hemorrhagic stroke. 3, 7
• Cardiovascular outcomes: In the FOURIER trial, evolocumab reduced major cardiovascular events by 15% and the composite of CV death, MI, or stroke by 20% over 2.2 years. 3, 7

---

Critical Pitfalls to Avoid

• Do not skip ezetimibe: Always add ezetimibe before considering PCSK9 inhibitors unless the patient is already on it. 1, 2
• Do not use PCSK9 inhibitors in HoFH patients with negative/negative LDLR mutations: These patients have <2% LDL receptor activity and will not respond. 1
• Do not delay treatment in very high-risk patients: If LDL-C remains >4.5 mmol/L (>180 mg/dL) despite statin + ezetimibe, initiate PCSK9-inhibitor therapy promptly. 1
• Do not use PCSK9 inhibitors for primary prevention in non-FH patients: These agents are reserved for secondary prevention or FH. 8